Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15612852 | 0.92 | SPHK1 (0.42) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL13964507 | 0.92 | SPHK1 (0.42) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL6917878 | 0.92 | SPHK1 (0.42) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL25305199 | 0.90 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30484720 | 0.90 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL13974156 | 0.89 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL23771902 | 0.89 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL209963 | 0.89 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3086684 | 0.89 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3310633 | 0.89 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | SPHK1 887/4885BRD4 1901/4885CHRM2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.